Lysosomal storage disease: Gene therapy on both sides of the blood-brain barrier

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Most lysosomal storage disorders affect the nervous system as well as other tissues and organs of the body. Previously, the complexities of these diseases, particularly in treating neurologic abnormalities, were too great to surmount. However, based on recent developments there are realistic expectations that effective therapies are coming soon. Gene therapy offers the possibility of affordable, comprehensive treatment associated with these diseases currently not provided by standards of care. With a focus on correction of neurologic disease by systemic gene therapy of mucopolysaccharidoses types I and IIIA, we review some of the major recent advances in viral and non-viral vectors, methods of their delivery and strategies leading to correction of both the nervous and somatic tissues as well as evaluation of functional correction of neurologic manifestations in animal models. We discuss two questions: what systemic gene therapy strategies work best for correction of both somatic and neurologic abnormalities in a lysosomal storage disorder and is there evidence that targeting peripheral tissues (e.g., in the liver) has a future for ameliorating neurologic disease in patients?

Original languageEnglish (US)
Pages (from-to)83-93
Number of pages11
JournalMolecular Genetics and Metabolism
Volume114
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Lysosomal Storage Diseases
Gene therapy
Nervous System Diseases
Blood-Brain Barrier
Genetic Therapy
Nervous System Malformations
Tissue
Mucopolysaccharidosis III
Mucopolysaccharidosis I
Nerve Tissue
Standard of Care
Neurologic Manifestations
Neurology
Animal Models
Liver
Animals
Therapeutics

Keywords

  • Behavior
  • CNS
  • Mucopolysaccharidosis
  • Neurologic
  • Sleeping beauty transposon
  • Transcytosis

Cite this

Lysosomal storage disease : Gene therapy on both sides of the blood-brain barrier. / Aronovich, Elena L; Hackett, Perry B.

In: Molecular Genetics and Metabolism, Vol. 114, No. 2, 01.02.2015, p. 83-93.

Research output: Contribution to journalReview article

@article{d8579d53b0dc454885216dad4366a0f3,
title = "Lysosomal storage disease: Gene therapy on both sides of the blood-brain barrier",
abstract = "Most lysosomal storage disorders affect the nervous system as well as other tissues and organs of the body. Previously, the complexities of these diseases, particularly in treating neurologic abnormalities, were too great to surmount. However, based on recent developments there are realistic expectations that effective therapies are coming soon. Gene therapy offers the possibility of affordable, comprehensive treatment associated with these diseases currently not provided by standards of care. With a focus on correction of neurologic disease by systemic gene therapy of mucopolysaccharidoses types I and IIIA, we review some of the major recent advances in viral and non-viral vectors, methods of their delivery and strategies leading to correction of both the nervous and somatic tissues as well as evaluation of functional correction of neurologic manifestations in animal models. We discuss two questions: what systemic gene therapy strategies work best for correction of both somatic and neurologic abnormalities in a lysosomal storage disorder and is there evidence that targeting peripheral tissues (e.g., in the liver) has a future for ameliorating neurologic disease in patients?",
keywords = "Behavior, CNS, Mucopolysaccharidosis, Neurologic, Sleeping beauty transposon, Transcytosis",
author = "Aronovich, {Elena L} and Hackett, {Perry B}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.ymgme.2014.09.011",
language = "English (US)",
volume = "114",
pages = "83--93",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lysosomal storage disease

T2 - Gene therapy on both sides of the blood-brain barrier

AU - Aronovich, Elena L

AU - Hackett, Perry B

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Most lysosomal storage disorders affect the nervous system as well as other tissues and organs of the body. Previously, the complexities of these diseases, particularly in treating neurologic abnormalities, were too great to surmount. However, based on recent developments there are realistic expectations that effective therapies are coming soon. Gene therapy offers the possibility of affordable, comprehensive treatment associated with these diseases currently not provided by standards of care. With a focus on correction of neurologic disease by systemic gene therapy of mucopolysaccharidoses types I and IIIA, we review some of the major recent advances in viral and non-viral vectors, methods of their delivery and strategies leading to correction of both the nervous and somatic tissues as well as evaluation of functional correction of neurologic manifestations in animal models. We discuss two questions: what systemic gene therapy strategies work best for correction of both somatic and neurologic abnormalities in a lysosomal storage disorder and is there evidence that targeting peripheral tissues (e.g., in the liver) has a future for ameliorating neurologic disease in patients?

AB - Most lysosomal storage disorders affect the nervous system as well as other tissues and organs of the body. Previously, the complexities of these diseases, particularly in treating neurologic abnormalities, were too great to surmount. However, based on recent developments there are realistic expectations that effective therapies are coming soon. Gene therapy offers the possibility of affordable, comprehensive treatment associated with these diseases currently not provided by standards of care. With a focus on correction of neurologic disease by systemic gene therapy of mucopolysaccharidoses types I and IIIA, we review some of the major recent advances in viral and non-viral vectors, methods of their delivery and strategies leading to correction of both the nervous and somatic tissues as well as evaluation of functional correction of neurologic manifestations in animal models. We discuss two questions: what systemic gene therapy strategies work best for correction of both somatic and neurologic abnormalities in a lysosomal storage disorder and is there evidence that targeting peripheral tissues (e.g., in the liver) has a future for ameliorating neurologic disease in patients?

KW - Behavior

KW - CNS

KW - Mucopolysaccharidosis

KW - Neurologic

KW - Sleeping beauty transposon

KW - Transcytosis

UR - http://www.scopus.com/inward/record.url?scp=84921803830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921803830&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2014.09.011

DO - 10.1016/j.ymgme.2014.09.011

M3 - Review article

C2 - 25410058

AN - SCOPUS:84921803830

VL - 114

SP - 83

EP - 93

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -